Regeneron Pharmaceuticals, Inc. Share Price and Company Fundamentals
Last traded: Yesterday at 8:00 PM
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||10715|
|Mailing address||777 Old Saw Mill River Road Tarrytown NY 10591-6707 United States|
|Phone / Fax||914 847 7000 /|
Regeneron Pharmaceuticals, Inc. paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.REGN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
REGN's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Oct 2022, following are the company executives and directors listed on Regeneron Pharmaceuticals, Inc..
|Dr. Leonard S. Schleifer M.D., Ph.D.||Founder, Pres, CEO & Director||68||6.47M|
|Dr. George D. Yancopoulos M.D., Ph.D.||Scientific Founder, Pres, Chief Scientific Officer & Director||61||6.4M|
|Mr. Robert E. Landry Jr.||Exec. VP of Fin. & CFO||57||1.9M|
|Mr. Joseph J. LaRosa||Exec. VP, Gen. Counsel & Sec.||62||1.75M|
|Dr. Andrew J. Murphy Ph.D.||Exec. VP of Research||62||1.57M|
|Mr. Daniel P. Van Plew||Exec. VP and GM of Industrial Operations & Product Supply||48||1.77M|
|Ms. Patrice Gilooly||Sr. VP of Quality Assurance & Operations|
|Mr. Christopher R. Fenimore||Sr. VP, Head of Accounting & Controller||50|
|Mr. Gerald Underwood||Sr. VP of Technical Operations|
|Mr. Bob McCowan||Sr. VP of IT & Chief Information Officer|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Regeneron Pharmaceuticals, Inc. is and its enterprise value is .
The REGN's stocks Beta value is 0.17 making it 83% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Frequently Asked Questions
1. What is Regeneron Pharmaceuticals, Inc.'s Stock Symbol?
Regeneron Pharmaceuticals, Inc. trades on NASDAQ under the ticker symbol "REGN".
2. What is Regeneron Pharmaceuticals, Inc.'s stock price today?
One share of REGN stock can currently be purchased for approximately $745.68.
3. How can I contact Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc.'s mailing address is 777 Old Saw Mill River Road Tarrytown NY 10591-6707 United States. The company can be reached via phone at 914 847 7000.
4. What is Regeneron Pharmaceuticals, Inc.'s official website?
The official website of Regeneron Pharmaceuticals, Inc. is https://www.regeneron.com.